Table 1.
Patients’ characteristics of the different BioRAIDs subpopulations.
| Clinical data | Mutation data | Mutation and CNV data | RPPA data | Mutation, CNV and RPPA data | ||
|---|---|---|---|---|---|---|
| Number of patients | 376 | 181 | 146 | 135 | 89 | |
| FIGO 2018 | I/II | 290 (77%) | 133 (73%) | 110 (75%) | 97 (72%) | 66 (74%) |
| III/IV | 86 (23%) | 48 (27%) | 36 (25%) | 38 (28%) | 23 (26%) | |
| PFS Event | 108 (29%) | 60 (33%) | 50 (34%) | 46 (34%) | 32 (36%) | |
| HPV Clade | Clade 7/HPV negative | 104 (28%) | 54 (30%) | 41 (28%) | 42 (31%) | 27 (30%) |
| Clade 9/Others | 220 (58%) | 126 (70%) | 104 (71%) | 93 (69%) | 62 (70%) | |
| NA | 52 (14%) | 1 (<1%) | 1 (<1%) | 0 | 0 | |
| Histology | Squamous | 308 (82%) | 148 (82%) | 118 (81%) | 112 (83%) | 72 (81%) |
| Adenocarcinoma | 43 (11%) | 19 (10%) | 16 (11%) | 15 (11%) | 11 (12%) | |
| Adenosquamous | 15 (4%) | 11 (6%) | 9 (6%) | 7 (5%) | 5 (6%) | |
| Mixed/undifferentiated. | 9 (2%) | 3 (10%) | 3 (2%) | 1 (<1%) | 1 (1%) | |
| NA | 1 (<1%) | 0 | 0 | 0 | 0 | |
| Initial Treatment | Chemoradioation | 242 (64%) | 112 (62%) | 89 (61%) | 89 (66%) | 55 (62%) |
| Surgery | 76 (20%) | 35 (19%) | 30 (21%) | 21 (16%) | 16 (18%) | |
| NACT | 58 (15%) | 34 (19%) | 27 (18%) | 25 (19%) | 18 (20%) | |
CNV= copy number variation; FIGO 2018 integrating lymph nodes status under IIIC; PFS=Progression free survival; HPV type (based on hybridisation test)2: Clade 9 (HPV 16.31.33.35.52.58) & Clade 7 (HPV 18.39.45.59.68); NACT=Neaodjuvant chemotherapy, NA=not available.